Many generic drugs are not truly bioequivalent to the original medicines they copy and switching to them can lead to worse patient outcomes, according to US researchers.
Johnson Matthey saw revenue from (active pharmaceutical ingredients) APIs increase in fiscal 2015 despite competition from generic manufacturers and the relocation of a key customer.
Opiate API manufacturer Macfarlan Smith has been fined £12,000 for failing to ensure the safety of an employee injured at its plant in Scotland in 2011.
Johnson Matthey’s API business had a mixed fiscal Q1 with gains made in ADHD ingredients and bulk opiates being accompanied by a decline in revenue from specialty opiates.
Biopharmaceuticals firm Shire will cease manufacture at its plant in Owings Mills, Maryland, US with the loss of 260 jobs in the latest stage of its plan to wind up the in-house production of small molecule drugs.
A milestone payment from Bristol-Myers Squibb for the successful advancement of a project into clinical development, along with strong sales by its contract research and manufacturing services unit, prompted Albany Molecular Research Inc (AMRI) to hike...
AMRI witnessed strong growth in two of its contract business during
the first quarter of 2008 although profit was impacted by its
dominant large-scale division, which lagged during the period.
An end may be in sight to the long-running problems with the
Florida manufacturing facility acquired by US brand and generic
company Watson Pharmaceuticals with Andrx Corporation in November
2006.
In the world of chemistry the majority of reactions are well known
and have been around for a very long time producing similar
compounds. It is not very often that a completely new reaction
methodology comes along which can turn something...
Shire and Noven Pharmaceuticals have announced the voluntary
withdrawal of a limited amount of Attention Deficit Hyperactivity
Disorder (ADHD) transdermal patches following reports of a
mechanical problem when applying the patch.
Johnson Matthey has announced a reassuring business update ahead of
its 31 March year-end, suggesting that Adderall is the driving
force behind a recovery in its pharmaceutical materials business.
British pharma company Shire has opened a new $6m (€4.7m)
pharmaceutical technology centre at its Baltimore, Maryland plant
in order to improve its manufacturing capability.
Drug giant Eli Lilly has joined forces with Suven Life Sciences in
a deal that will focus on pre-clinical research of molecules in the
therapeutic area of central nervous system (CNS) disorders.
Albany Molecular Research (AMRI) has announced a multi-year drug
substance manufacturing agreement with New River Pharmaceuticals,
as its attention deficit hyperactivity disorder (ADHD) medicine
looks set to hit the market.
Determined to slash operational costs, Eli Lilly has decided to
shut down its pill and tablet manufacturing plant in Basingstoke
and boost production in its remaining three dry product sites.
Biophan has filed the first patent to come out of its newly-formed
relationship with NaturalNano to develop new and improved ways of
controlled-release drug delivery.
Shire, Britain's third-biggest drugmaker, has won approval in the
US for Daytrana, a methylphenidate skin patch developed with
Noven's transdermal technology, making it the first non-oral
medication for the treatment of...
Supernus Pharmaceuticals has acquired the drug formulation business
of Shire Laboratories (SLI) in a move that strengthens the
pharmaceutical technologies and services. The company will make use
of the patents to improve its own portfolio...
Researchers have discovered a new mechanism that reveals how high
levels of a neurotransmitter exerts its effect on the brain. The
findings provide new research avenues to understand and potentially
manage neurotransmitter-related...
The manufacturing compliance problems affecting US generic drug
manufacturer Able Laboratories, which have prompted a huge recall
of its entire product range, show little signs of being resolved,
reports Phil Taylor.
Newly discovered serotonin pathways in the nervous system are
providing a path toward future pharmaceutical treatments for
depression and other disorders such as depression, anxiety, sudden
infant death syndrome, attention deficit...
Dermatrends, a US drug delivery company, has been awarded a patent
that covers the method of using bases to enhance the permeation of
amine drugs across the skin and could lead to new products for
Alzheimer's and other diseases.
A once-daily version of a drug for attention deficit problems in
children - originally designed to avoid the stigma of having to
take medication during school hours - could also save lives on the
road, according to new research.
